EGM
MACK

Engineers Gate Manager’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Engineers Gate Manager’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,556
Closed -$113K – 906
2017
Q2 		$113K Buy
+11,556
New +$236K 0.01% 611

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Engineers Gate Manager's MACK Position: Q3 2017 in Review

Engineers Gate Manager sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 11,556 shares — an estimated $113K sold.

Engineers Gate Manager first reported a position in MACK in Q2 2017 and held it in 1 quarter. The position peaked at $113K in Q2 2017. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Engineers Gate Manager reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Engineers Gate Manager sold 11,556 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $113K.
  • Engineers Gate Manager first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Engineers Gate Manager's Merrimack Pharmaceuticals, Inc. position peaked at $113K in Q2 2017.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Engineers Gate Manager's 13F filing for Q3 2017, filed 13 Nov 2017.